GTR

Investor Presentation

DISCLAIMER

Certain information set forth in this presentation contains "forward-looking information", including "future-oriented financial information" and "financial outlook", under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company's business, projects, and joint ventures; (iv) execution of the Company's vision and growth strategy, including with respect to future mergers and acquisitions activity and global growth; (v) sources and availability of third-party financing for the Company's projects; (vi) completion of the Company's projects that are currently underway, in development or otherwise under consideration; (vi) renewal of the Company's current customer, supplier and other material agreements; and (vii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.

These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

OUR THESIS

Advances in bio- and computational technology mean that **for the first time in history, any biological system can be customized and optimized for specific commercial parameters**.

This paradigm shift will drive tremendous growth in markets for bio-engineered and bio-manufactured outputs.

We create value by applying the **most sophisticated bio-computational and engineering technologies to key markets for organisms and their outputs.**

OUR COMPANY

LEADING PLATFORM

Founded in 2017, GT Research has constructed a unique, powerful platform that combines computational genomics, data science, and bio-engineering.

ROOTED IN SCIENCE

GTR's best-in-class science team includes academic scientists with extensive expertise in computational biology, data science, algorithm development, and gene discovery and modification.

DIFFERENTIATED EXPERTISE

Dr. Glen Borchert, GTR's Chief Geneticist, was a postdoc at the Berkeley laboratory of Dr. Jennifer Doudna during the development of CRISPR CaS-9 gene editing technology, which was awarded the Nobel Prize in 2020.

PROPRIETARY IP

COMPUTATIONAL BIOLOGY AND DATA SCIENCE

GTR believes that **proprietary computational resources** are foundational for sustainable and significant value creation in the biotech sector.

An organism's **genome is its core "data set" –** analyzing and extracting insight from this data is a **necessary prerequisite** for optimization.

GTR's computational platform, 2+ years in development, is a suite of proprietary software tools that allow for **turnkey sequencing, comparative analysis, and gene discovery** of the genome of any organism.

In sum, the platform allows GTR to **"manufacture" valuable intellectual property** through computational-based gene discovery at scale.

SCIENCE TEAM

Michael Francis, PhD
Chief Science Officer

- Assistant Professor of Physiology and Cell Biology at the University of South Alabama College of Medicine and Center for Lung Biology.
- Experienced research scientist with extensive knowledge of genomics, biophysics, and computational analytics.
- B.Sc. in Physics from Auburn University and a PhD in Physiology from the University of South Alabama.



Glen Borchert, PhD
Chief Geneticist

- Postdoctoral fellowship at University of California, Berkeley under Dr. Jennifer Doudna, inventor of CRISPR-Cas9 gene editing technology.
- Associate Professor of Pharmacology at the University of South Alabama College of Medicine.
- Ph.D. in Interdisciplinary Genetics from the University of Iowa.
- Dr. Borchert's lab has published more than 25 articles in peer-reviewed journals and received numerous awards.

Nick Ainslie, MSc
VP of Business Development and Customer Success

- Career in biology studying algae, monitoring water quality and ecosystem health of the wild waterways of California.
- Research focused mainly on gene regulation in relation to seasonal cycles in their ecosystems.
- Spearheaded projects globally in the biomedical, pharmaceutical, environmental, agricultural technology, and policy arenas.

MANAGEMENT TEAM

Sam Proctor

Chief Executive Officer

- Founder of GTR.
- Over seven years as financial services regulatory and transactional lawyer with extensive experience across corporate strategy, transactions and regulatory optimization in the financial services sector.
- Holds a JD from the University of Chicago Law School and a BSE from the Wharton School of the University of Pennsylvania.

Damian Kassack

Chief Revenue Officer

- Focused on business development, sales, marketing, pricing, and customer success.
- Previously a Managing Director in Accenture's strategy practice.
- MBA from Duke University, The Fuqua School of Business, and a BS in Business Administration from the University of Richmond.

Peter McKinney

Chief Technology Officer

- Oversees all technology-related initiative at the firm.
- Experienced full stack developer currently working in the Microsoft .NET ecosystem with a specialization in Angular front-end development.
- Holds a Bachelor's Degree in Computer Science, with concentrations in AI, Linux System Administration, and Embedded Systems from the University of West Florida.

Dimitri Samaratunga

Chief Operations Officer

- Oversees all technology-related initiative at the firm.
- Experienced full stack developer currently working in the Microsoft .NET ecosystem with a specialization in Angular front-end development.
- Holds a Bachelor's Degree in Computer Science, with concentrations in AI, Linux System Administration, and Embedded Systems from the University of West Florida.

REVENUE MODEL

FROM USE CASE TO MARKET

Ex. Customer Pain Points:

- **Customized output of desired tryptamines / cannabinoids**
- **Customized phenotypes for specific clinical applications (e.g., pain relief)**
- **Mold and pest resistance, improved productivity, standardization**

1. CONSULTATION

Scientific research review and commercial feasibility study

2. TARGET IDENTIFICATION

Pinpoint genes and create technical roadmap

3. SAMPLE CREATION

Produce optimized organism

4. REVENUE GENERATION

Sales through distribution partners and licensing of proprietary assets

MILESTONES

2018 – 2019:
Developing the platform

Jan 2018 — Start construction of bioinformatics platform

Jun 2019 — Completed first working version of bioinformatics platform

Dec 2019 — Tested and validated ability for bioinformatics platform to derive novel discoveries

2020:
First discovery, first customers

Jan 2020 — Market need for THC null hemp phenotype triggers discoveries re: THCAS gene pathway

Apr-July 2020 — First customers signed

Dec 2020 — LOI for 50M seeds (THC null phenotype)

2021:
Growing the business and expanding scope

Jan 2021 — Scope expanded to include agricultural pathogens and psychedelics; acquired new customers

Mar 2021 — Begin Series A round to fund growth and scaling

GTR

CASE STUDY

THE NULL HEMP PHENOTYPE

Sample P&L
(THC Null Phenotype, 5 Years)

Gross Sales of Customized Strain (Plants, Seeds)	$100M
- Cost of Goods Sold	($25M)
Margin from Sales of Modified Organisms	**$75M**
+ Licensing Revenue from Customized Strain IP	$15M
- SPV Operating Expenses (insurance, legal, etc.)	($10M)
Net Income Available to Investors	**$80M**

GTR

CASE STUDY

AGRICULTURAL PATHOGENS – *XYLELLA FASTIDIOSA*

GTR is focusing the Platform's scope of deployment to include the genetic determinants for resistance to agricultural pathogens.

Limited understanding of the genetic determinant of *Xylella* resistance

Extreme economic impact of pathogen across multiple crops

No current *Xylella* resistant varieties available in the market

1. **Apply proprietary platform and genomic analysis**
2. **Develop customized, IP-protected Olive and other crop phenotypes that will proliferate across the market and significantly mitigate the economic impact of this pathogen.**

CASE STUDY

PSYCHEDELICS – *P. CUBENSIS*

GTR is rapidly expanding the Platform's scope of deployment to include psychedelics and the plant medicine ecosystem.

Poor / nonexistent scientific understanding of organism genomes

Inefficiency in scaling production

Inability to produce consistent, standardized outputs

1. **Apply proprietary platform and genomic analysis**
2. **Develop customized, IP-protected *P. cubensis* phenotype that will become phenotype of choice across marketplace**

GTR

GOING FORWARD

SERIES A

$2M raise @ $10M valuation

SEED ROUND

$5M valuation

SEEKING STRATEGIC INVESTORS

Partners who understand GTR's unique value proposition and capabilities

Because GTR's cost base is modest, the Series A should be last external fundraise required.

CONTACT

Sam Proctor
Chief Executive Officer
646-522-8478
sam@gtresearch.io

Damian Kassack
Chief Revenue Officer
212-991-8303
damian@gtresearch.io